Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)

Blood

Volumn 102, Issue 10, 2003, Pages 3587-3591

  Hall, Claire ^b   Richards, Stephen ^b   Hillmen, Peter ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CELL CLONE; CELL SIZE; CONTROLLED STUDY; DRUG CONTRAINDICATION; FOLLOW UP; GRANULOCYTE; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

EID: 0242494954     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0009     Document Type: Article

References (21)

1. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-1258.
2. Socie G, Mary JY, de-Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996;348:573-577.
3. Miyata T, Takeda J, lida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993;259:1318-1320.
4. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703-711.
5. Nishimura J, Murakami Y, Kinoshita T. Paroxysmal nocturnal hemoglobinuria: an acquired genetic disease. Am J Hematol. 1999;62:175-182.
6. Takahashi M, Takeda J, Hirose S, et al. Deficient biosynthesis of N-acetylglucosaminylphosphatidylinositol, an early intermediate of GPI anchor biosynthesis in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J Exp Med. 1993;177:517-521.
7. Hillmen P, Bessler M, Mason P, Watkins WM, Luzzatto L. Specific defect in N-acetylglucosamine incorporation in the GPI anchor synthetic pathway in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A. 1993;90:5272-5276.
8. Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989;84:7-17.
9. Yamashina M, Ueda E, Kinoshita T, et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1990;323:1184-1189.
10. Hugel B, Socie G, Vu T, et al. Elevated levels of circulating procoagulaht microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anaemia. Blood. 1999;93:3451-3456.
11. Gralnick HR, Vail M, McKeown LP, et al. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1995;91:697-702.
12. Ploug M, Plesner T, Ronne E, et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood. 1992;79:1447-1455.
13. Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry. 2000;42:223-233.
14. Richards SJ, Hillmen P. Immunophenotypic analysis of PNH cells. In: Robinson JP, ed. Current Protocols in Cytometry. Vol 1. New York, NY: J Wiley & Sons; 2002:6:11:1-6:11:14.
15. Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2000;108:470-479.
16. Jin JY, Tooze JA, Marsh JC, Gordon-Smith EC. Glycosylphosphatidyl-inositol (GPI)-Iinked protein deficiency on the platelets of patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria: two distinct patterns correlating with expression on neutrophils. Br J Haematol. 1997;96:493-496.
17. Nafa K, Bessler M, Mason P, et al. Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis. Haematologica. 1996;81:540-542.
18. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation. Br J Haematol. 2001;114:271-280.
19. White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S. Management and prognosis of life-threatening bleeding during warfarin therapy: National Consortium of Anticoagulation Clinics. Arch Intern Med. 1996;156:1197-1201.
20. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423-428.
21. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99.